Clinical Trials on Pre-diabetic in Japan

Total 510 results

Eli Lilly and Company

Active, not recruiting

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)

Type 2 Diabetes

Japan
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes (SURPASS J-mono)

Type 2 Diabetes

Japan
Takeda

Completed

Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

Diabetes Mellitus

Japan
AstraZeneca

Completed

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment (EasyMix)

Diabetes Mellitus, Type 2 | Diabetes

Japan, China
AstraZeneca

Completed

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Diabetes Attitudes Wishes and Needs (DAWN2)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare Professionals

Spain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes | High Blood Sugar

Japan
Theracos

Completed

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Type 2 Diabetes Mellitus

United States, Japan, Czechia, Hungary, Poland, Spain
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Type 2 Diabetes Mellitus (T2DM)

Japan
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Eli Lilly and Company

Completed

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes (AWARD-JPN)

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease | Type 2 Diabetes Mellitus (T2DM) | Hypoglycemic Agents

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Sanofi
Kowa Company, Ltd.

Completed

TOFO Insulin Combination Trial

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Type 2 Diabetes Mellitus

Korea, Republic of, China, Japan, Taiwan, India
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1)

Diabetes Mellitus, Type 2

Finland, Taiwan, United States, Korea, Republic of, China, Australia, Portugal, Japan, India, Russian Federation, Norway, Italy, Mexico, Turkey, Poland, Belgium, Bulgaria, Croatia, Puerto Rico, Romania, Serbia, South Africa
Theracos

Completed

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Type2 Diabetes Mellitus

United States, Japan
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (SURPASS-1)

Type 2 Diabetes Mellitus

United States, Japan, India, Puerto Rico, Mexico
Pfizer

Completed

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Macular Edema | Retinal Disease | Diabetic Mellitus

Japan
Novo Nordisk A/S

Completed

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs (DUAL™ II Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Takeda

Completed

Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (SURPASS-5)

Type 2 Diabetes

United States, Puerto Rico, Spain, Japan, Germany, Czechia, Poland, Slovakia
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, Japan, Malaysia, Taiwan, Thailand, Hong Kong
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (PIONEER 10)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Bayer

Completed

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone (ARTS-HF Japan)

Heart Failure

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novartis

Completed

Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema (REVEAL)

Diabetic Macular Edema

Hong Kong, Taiwan, Singapore, Korea, Republic of, China, Japan
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
AstraZeneca

Completed

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Type 2 Diabetes

Japan
Eli Lilly and Company

Recruiting

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

Type 2 Diabetes

United States, Japan, China, Puerto Rico, Romania, Brazil
AstraZeneca

Completed

Specific Clinical Experience Investigation for Long-term Use of Bydureon.

Type 2 Diabetes

Japan
Hoffmann-La Roche

Completed

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, Hong Kong, Romania, United States, Japan, Russian Federation, Spain, Canada, Germany, Latvia, Mexico, Brazil

3

Subscribe